Bausch + Lomb raises 2026 guidance as Q3 revenue grows (BLCO:NYSE)
Bausch + Lomb reported Q3 Non-GAAP EPS of $0.34, exceeding estimates by $0.12. Revenue grew 7.8% year-over-year to $1.38 billion, also beating forecasts. The company raised its 2026 guidance, targeting revenue of $5.45 billion to $5.55 billion and adjusted EBITDA of $1.09 billion to $1.14 billion, excluding acquired IPR&D.
How this was made
The 30-second read
Why it matters
The guidance beat is likely to drive short‑term price appreciation.
Market read
First‑report earnings guidance lift for a mid‑cap health‑care stock.
What to watch
Potential supply‑chain constraints or regulatory hurdles could temper the upside.
Background
Bausch + Lomb released its Q3 results and FY2026 outlook via a press release.
Ticker impact
Bausch + Lomb raised FY2026 revenue guidance to $5.45‑$5.55B and adjusted EBITDA to $1.09‑$1.14B, above consensus estimates.
potential upside as the market prices in the higher guidance
Guidance lift is material and first reported, indicating improved financial performance.
Market effects
May lift other ophthalmic and medical device stocks as sector outlook improves.
US healthcare sector could see modest gains.
Limited to investors tracking US-listed health‑care companies.
Counterpoint
If the guidance is overly optimistic, future earnings could miss, leading to a pull‑back.
Key entities
- companyBausch + Lomb
US‑listed ophthalmic and eye‑care products manufacturer.
